DURECT Corp
NASDAQ:DRRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
DURECT Corp
NASDAQ:DRRX
|
US |
|
Dayu Water-saving Group Co Ltd
SZSE:300021
|
CN |
|
F
|
FlexQube AB (publ)
STO:FLEXQ
|
SE |
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
HK |
|
Nextracker Inc
NASDAQ:NXT
|
US |
|
Physiomics PLC
LSE:PYC
|
UK |
|
F
|
Flexion Mobile PLC
STO:FLEXM
|
UK |
|
G
|
Graycliff Exploration Ltd
CNSX:GRAY
|
CA |
|
ME Group International PLC
LSE:MEGP
|
UK |
|
N
|
Nyocor Co Ltd
SSE:600821
|
CN |
|
Energy Focus Inc
NASDAQ:EFOI
|
US |
DURECT Corp
DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. The company is headquartered in Cupertino, California and currently employs 79 full-time employees. The company went IPO on 2000-09-28. The firm's product candidates include DUR-928 oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. The Company’s other commercial product candidates include POSIMIR, PERSERIS and Methydur Sustained Release Capsules. The firm is conducting a Phase IIb study (AHFIRM) of larsucosterol (DUR-928) in subjects with severe alcohol-associated hepatitis (Alcoholic Hepatitis (AH) to evaluate the safety and efficacy of larsucosterol treatment. Larsucosterol (DUR-928) is lead product candidate, an endogenous sulfated oxysterol and an epigenetic regulator. The firm focuses on drug delivery technology around its SABER and CLOUD Bioerodible Injectable Depot Systems. SABER uses a high viscosity base component, such as sucrose acetate isobutyrate (SAIB), to provide controlled release of a drug.
DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. The company is headquartered in Cupertino, California and currently employs 79 full-time employees. The company went IPO on 2000-09-28. The firm's product candidates include DUR-928 oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. The Company’s other commercial product candidates include POSIMIR, PERSERIS and Methydur Sustained Release Capsules. The firm is conducting a Phase IIb study (AHFIRM) of larsucosterol (DUR-928) in subjects with severe alcohol-associated hepatitis (Alcoholic Hepatitis (AH) to evaluate the safety and efficacy of larsucosterol treatment. Larsucosterol (DUR-928) is lead product candidate, an endogenous sulfated oxysterol and an epigenetic regulator. The firm focuses on drug delivery technology around its SABER and CLOUD Bioerodible Injectable Depot Systems. SABER uses a high viscosity base component, such as sucrose acetate isobutyrate (SAIB), to provide controlled release of a drug.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
